Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04851418
Other study ID # NL71897.100.19
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 1, 2020
Est. completion date February 2022

Study information

Verified date April 2021
Source St. Antonius Hospital
Contact JM ten Berg, Prof. Dr.
Phone +31883201232
Email j.ten.berg@antoniusziekenhuis.nl
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Overcrowding in the emergency department is an increasing problem in hospitals worldwide. Point-of-care Troponin (POC cTn) testing combined with a well investigated risk stratification tool (HEART-score) used in the ambulance may contribute to more rapidly diagnostics of ruling in or ruling out myocardial infarctions (MI) and subsequently reduce unnecessary hospital admissions, total admission time and costs. However, the applicability of the POC cTn and the HEART-score in the pre-hospital setting remains unclear. This study will evaluate this applicability.


Description:

Co-primary Objectives: 1. To evaluate the interobserver agreement of the HEART-score performed by ambulance personnel compared to the HEART-score performed by emergency physicians. 2. To evaluate the diagnostic performance of a strategy based on a pre-hospital HEART-score (with POC cTn testing) or combined with an adjuvant single hs-cTn test at the emergency department to rule-in or rule-out acute coronary syndrome (ACS). 3. To evaluate the diagnostic performance of (serial) POC cTn testing or combined with hs-cTn testing compared to (serial) hs-cTn testing to rule-in or rule-out MI. 4. To investigate the feasibility of using the pre-hospital HEART-score and POC cTn in the 0/1 hour algorithm to rule-out ACS. Secondary Objectives: 5. To evaluate the occurrence of major adverse cardiac events (MACE) in all included patients with a follow up time of 30 days from first medical contact. 6. To evaluate the patient reported outcome measures (PROMs) in all chest pain patients transported to the hospital at baseline and at 30 days 7. To perform a cost-analysis of an early diagnostic strategy using the pre-hospital HEART-score Study design: A prospective, observational, single multicentre study Study population: Total number of patients needed for analysis: n=650 Inclusion criteria: - All out-of-hospital chest pain patients visited by an ambulance - Transportation to a hospital with working diagnosis NSTE-ACS - Age ≥ 18 years Exclusion criteria: - Comatose state, hemodynamic instability or shock - Electrocardiographic ST-segment elevation in the pre-hospital setting treated as STEMI - No pre-hospital 12-lead electrocardiogram performed or available - An obvious non-cardiac cause for the chest pain (trauma, etc.) - Suspicion of aortic dissection or pulmonary embolism - Cognitive impairment - Pregnancy - Suspicion of COVID-19 by ambulance Study procedures: The HEART-score and the POC cTn will be calculated in all included patients in the pre-hospital phase. Simultaneously, a venous blood sample will be drawn from the venous access site for later hs-cTn testing. Outcomes of any pre-hospital study measurements (i.e. pre-hospital POC cTn results or calculated pre-hospital HEART-scores) are blinded to the physicians at the ED and will not affect usual care. According to current practice, all patients will be transported to the hospital for further evaluation. At the emergency department (ED) all included patients will undergo regular hs-cTn testing and HEART-score assessment performed by emergency physicians (standard care), and an extra venous blood sample will be drawn for this study. Additional cTn tests (POC and hs-cTn) will be performed in the laboratory. Main study parameters/endpoints: 1. HEART-score agreement (interobserver variability between pre-hospital and in-hospital HEART-score assessment) 2. Final diagnosis of NSTE-ACS at discharge 3. Myocardial infarction at discharge Secondary study parameters/endpoints: 4. Composite endpoint (cardiovascular mortality, myocardial infarction, urgent revascularisation) at 30 days 5. Angina frequency and stability, physical limitations, treatment satisfaction, quality-of-life, cardiac anxiety and depression (SAQ, PHQ-4) Follow-up: Total follow-up duration is 30 days after initial presentation. Other demographic and clinical parameters at baseline will be taken into account. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: All patients will undergo a POC cTn test performed by ambulance personnel. In all patients, two venous blood samples will be drawn in the pre-hospital phase (1x) and at the emergency department (1x). Besides the minimal risks of performing a POC finger prick test, no other risks are involved with study participation. All patients will be asked to fill in questionnaires (i.e. SAQ, PHQ-4) at baseline and at follow-up.


Recruitment information / eligibility

Status Recruiting
Enrollment 650
Est. completion date February 2022
Est. primary completion date January 2022
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - All out-of-hospital chest pain patients visited by an ambulance - Transportation to a hospital with working diagnosis NSTE-ACS - Age = 18 years Exclusion Criteria: - Comatose state, hemodynamic instability or shock - Electrocardiographic ST-segment elevation in the pre-hospital setting - No pre-hospital 12-lead electrocardiogram performed or available - An obvious non-cardiac cause for the chest pain (trauma, etc.) - Suspicion of aortic dissection or pulmonary embolism - Cognitive impairment - Pregnancy

Study Design


Intervention

Device:
Possible NSTE-ACS
As mentioned in the group description

Locations

Country Name City State
Netherlands St Antonius Hospital Nieuwegein
Netherlands Diakonessenhuis Utrecht Utrecht

Sponsors (3)

Lead Sponsor Collaborator
St. Antonius Hospital Abbott, Diakonessenhuis, Utrecht

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Heart score agreement HEART-score agreement (interobserver variability between pre-hospital and in-hospital HEART-score assessment): the calculated heart score by the ambulance will be subtracted from the calculated score of the emergency department. The minimum value could be -10 and the maximum value could be +10. A positive score means that the ambulance estimates the patient to be sicker or at higher risk. A negative value means that the ED estimates the patient to be sicker/at higher risk for developing major adverse cardiac events. 1 year
Primary Number of participants with final diagnosis of NSTE-ACS final diagnosis of NSTE-ACS (non-ST elevation myocardial infarction and unstable angina pectoris) at discharge 1 year
Primary Number of participants with final diagnosis of myocardial infarction at discharge Myocardial infarction at discharge 1 year
Secondary Number of participants with a composite endpoint 4. The composite endpoint exists out of cardiovascular mortality, myocardial infarction, urgent revascularisation at 30 days 30 days
Secondary Patient reported outcome measure: Seattle Angina questionnaire (SAQ) In order to gain information regarding how patients experience their disease, 2 questionnaires will be sent. The first questionnaire; Seattle Angina questionnaire will assess: angina frequency and stability, physical limitations, treatment satisfaction, and quality-of-life. 30 days
Secondary Patient reported outcome measure: Patient Health Questionnaire 4 In order to gain information regarding how patients experience their disease, 2 questionnaires will be sent. The second questionnaire will be the Patient Health Questionnaire 4, will discuss topics such as anxiety, depression and general psychological distress. 30 days
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A